The neurodegeneration in Alzheimer disease and the prion protein

10Citations
Citations of this article
57Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The concept of "prion-like" has been proposed to explain the pathogenic mechanism of the principal neurodegenerative disorders associated with protein misfolding, including Alzheimer disease (AD). Other evidence relates prion protein with AD: the cellular prion protein (PrPC) binds β amyloid oligomers, allegedly responsible for the neurodegeneration in AD, mediating their toxic effects. We and others have confirmed the high-affinity binding between β amyloid oligomers and PrPC, but we were not able to assess the functional consequences of this interaction using behavioral investigations and in vitro tests. This discrepancy rather than being resolved with the classic explanations, differencies in methodological aspects, has been reinforced by new data from different sources. Here we present data obtained with PrP antibody that not interfere with the neurotoxic activity of β amyloid oligomers. Since the potential role of the PrPC in the neuronal dysfunction induced by β amyloid oligomers is an important issue, find reasonable explanation of the inconsistent results is needed. Even more important however is the relevance of this interaction in the context of the disease, so as to develop valid therapeutic strategies. © 2012 Landes Bioscience. Do not distribute.

Cite

CITATION STYLE

APA

Forloni, G., Sclip, A., Borsello, T., & Balducci, C. (2013). The neurodegeneration in Alzheimer disease and the prion protein. In Prion (Vol. 7, pp. 60–65). https://doi.org/10.4161/pri.23286

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free